Professor of Pathology, University of Washington · Director, Dog Aging Project
Kaeberlein is the world's leading rapamycin researcher in the context of aging. His Dog Aging Project is testing rapamycin in companion dogs — a uniquely powered natural experiment. He argues that rapamycin is the most promising longevity intervention currently available to humans.
| Molecule | Dose | Timing | Tier | Hallmarks | Cart |
|---|---|---|---|---|---|
Rapamycin Prescription only. Kaeberlein is one of the most vocal advocates for low-dose weekly rapamycin. | 5–6 mg / week | Once weekly with grapefruit juice (increases bioavailability) | II | Nutrient-sensing dysreg.Cellular senescence | Rx only |
Omega-3 | 1–2 g | With meal | I | Microbiome alterationsDisabled autophagy | |
Vitamin D3 | 2000–4000 IU | Morning | I | Disabled autophagy | |
Acarbose Prescription only. ITP-validated in mice. | 100 mg with meals | With carbohydrate meals | II | Nutrient-sensing dysreg. | Rx only |
Tier I = multiple RCTs in humans · Tier II = human trials, early stage · Tier III = mechanism / animal studies only
Kaeberlein uses rapamycin personally and is transparent about the risks and unknowns. He is careful to distinguish his personal choices from clinical recommendations. The Dog Aging Project will provide the most rigorous mammalian data on rapamycin and aging within the next 3–5 years.
4 of 4 molecules are available in the index.
See how Matt's stack compares to Attia, Sinclair, Patrick, Huberman, and Johnson side-by-side.
Open comparison tool →